LUND, Sweden, Jan. 27, 2020 /PRNewswire/ -- Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced that the patient enrollment in an investigator-initiated phase 2 study to evaluate safety, tolerability and efficacy of imlifidase...
from PR Newswire: https://ift.tt/37uyIcP
No comments:
Post a Comment